Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Women's Insights on Extended Adjuvant Endocrine Therapy for Breast Cancer: Qualitative Online Forums Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: JMIR Publications Country of Publication: Canada NLM ID: 100959882 Publication Model: Electronic Cited Medium: Internet ISSN: 1438-8871 (Electronic) Linking ISSN: 14388871 NLM ISO Abbreviation: J Med Internet Res Subsets: MEDLINE
    • بيانات النشر:
      Publication: <2011- > : Toronto : JMIR Publications
      Original Publication: [Pittsburgh, PA? : s.n., 1999-
    • الموضوع:
    • نبذة مختصرة :
      Background: In France, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death among women. For around one-third of women with hormone receptor-positive breast cancer, extending adjuvant endocrine therapy (AET) beyond the initial 5 years is now recommended to reduce the risk of recurrence and mortality. While weighing benefits against potential side effects is essential, little is known about how women seek information about extended AET or how they experience this extension.
      Objective: This study aimed to explore, through online forums, women's unmet information needs, the factors influencing their decision-making around extended AET, and the needs and expectations they share throughout the treatment journey.
      Methods: A qualitative content analysis was conducted using data from 5 French online forums over a 10-year period. We used a nonparticipant observational approach to identify relevant posts and gain a deeper understanding of forum dynamics related to extended AET. Data were collected in March 2025. After applying inclusion and exclusion criteria, 188 messages posted by 105 women were selected. A netnographic approach, derived from ethnography and suited to exploratory research, was used in conjunction with Braun and Clarke's 6-phase framework for thematic analysis, integrating both inductive (narrative-based) and deductive (literature-informed) approaches.
      Results: Our findings showed that women turned to forums to seek information about extended AET from both medical and nonexpert sources. However, they often reported difficulties in interpreting complex or inconsistent information. Understanding and acceptance of treatment extension were influenced by the timing and manner of information disclosure. Three decision-making patterns were identified: (1) acceptance, (2) hesitation, and (3) refusal, which could shift over time, shaped by factors such as fear of recurrence, side effect experience and management, trust in treatment effectiveness, interactions with health care professionals, and life changes. Some women on extended AET shared resilient and encouraging experiences, providing reassurance and practical strategies for coping with side effects.
      Conclusions: Online forums offer valuable insights into women's experiences, unmet information needs, uncertainties, and coping strategies surrounding extended AET, contributing to addressing a gap in knowledge on how women perceive and manage long-term treatment. Providing clear, accessible information and tailored communication tools, especially on benefit-risk balance and side effects management, at the time of prescription and at key points along the care pathway, may support informed decision-making, improve treatment adherence, maintain quality of life, and offer reassurance. With growing numbers of women in long-term treatment, enhanced coordination between primary care and hospital services, including follow-up by trained general practitioners and gynecologists in collaboration with cancer centers, may help ensure continuity of care and comprehensive support.
      (© Geraldine Cazorla, Lorene Seguin, Magali Provansal, Sandrine De Montgolfier, Julien Mancini. Originally published in the Journal of Medical Internet Research (https://www.jmir.org).)
    • References:
      Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. (PMID: 35623026)
      Breast Cancer Res Treat. 2018 Feb;167(3):615-633. (PMID: 29110151)
      Eur J Cancer. 2022 Sep;172:53-64. (PMID: 35753212)
      JCO Oncol Pract. 2022 Aug;18(8):578-583. (PMID: 35344398)
      Lancet. 2013 Mar 9;381(9869):805-16. (PMID: 23219286)
      J Natl Compr Canc Netw. 2021 May 01;19(5):484-493. (PMID: 34794122)
      Cochrane Database Syst Rev. 2024 Jan 29;1:CD001431. (PMID: 38284415)
      Support Care Cancer. 2015 Nov;23(11):3115-30. (PMID: 25744290)
      J Cancer Surviv. 2017 Dec;11(6):808-821. (PMID: 28601981)
      Med Decis Making. 2017 Jan;37(1):79-90. (PMID: 27053528)
      J Med Internet Res. 2017 May 23;19(5):e175. (PMID: 28536093)
      Cancer Med. 2024 Feb;13(3):e6937. (PMID: 38240343)
      J Med Internet Res. 2018 Jun 14;20(6):e222. (PMID: 29903695)
      J Cancer Educ. 2021 Dec;36(6):1253-1260. (PMID: 32358717)
      Healthcare (Basel). 2021 Jun 07;9(6):. (PMID: 34200326)
      BMC Womens Health. 2025 Jan 3;25(1):1. (PMID: 39754199)
      Crit Rev Oncol Hematol. 2020 Dec;156:103114. (PMID: 33045493)
      J Clin Oncol. 2014 Jul 20;32(21):2255-69. (PMID: 24868023)
      J Natl Cancer Inst. 2018 Jan 1;110(1):. (PMID: 28922787)
      Eur J Oncol Nurs. 2023 Feb;62:102259. (PMID: 36623339)
      Breast. 2016 Apr;26:31-45. (PMID: 27017240)
      BMJ. 2004 May 15;328(7449):1148-9. (PMID: 15142894)
      Psychooncology. 2010 May;19(5):472-9. (PMID: 19507263)
      CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
      Eur J Oncol Nurs. 2020 Feb;44:101706. (PMID: 32007696)
      Patient Prefer Adherence. 2018 Feb 16;12:291-300. (PMID: 29497284)
      Lancet Oncol. 2021 Jul;22(7):e303-e313. (PMID: 33891888)
      Breast Cancer Res Treat. 2016 Jul;158(2):395-405. (PMID: 27339067)
      Lancet. 2015 Oct 3;386(10001):1341-1352. (PMID: 26211827)
      J Oncol Pract. 2019 Feb;15(2):106-107. (PMID: 30523754)
      Front Oncol. 2022 Oct 27;12:1039320. (PMID: 36387136)
      J Cancer Surviv. 2021 Feb;15(1):29-39. (PMID: 32804353)
      Health Expect. 2017 Aug;20(4):788-796. (PMID: 27899006)
      Psychooncology. 2006 Nov;15(11):1001-13. (PMID: 16511899)
      Cancers (Basel). 2020 Dec 31;13(1):. (PMID: 33561076)
      Support Care Cancer. 2020 Nov;28(11):5075-5084. (PMID: 32601852)
      Ann Oncol. 2019 Oct 1;30(10):1674. (PMID: 31236598)
      Nat Rev Drug Discov. 2003 Mar;2(3):205-13. (PMID: 12612646)
      BMC Cancer. 2018 Jul 11;18(1):732. (PMID: 29996816)
      Ann Oncol. 2019 Nov 1;30(11):1776-1783. (PMID: 31504126)
      N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
      Gynecol Obstet Fertil Senol. 2024 Jul-Aug;52(7-8):466-472. (PMID: 38342238)
      Cancers (Basel). 2023 Aug 21;15(16):. (PMID: 37627218)
      Patient Educ Couns. 2015 May 30;:. (PMID: 26054455)
      ESMO Open. 2025 May;10(5):105057. (PMID: 40279882)
      J Natl Cancer Inst. 2025 Aug 01;117(8):1573-1582. (PMID: 40163701)
      Med Oncol. 2017 Jul;34(7):131. (PMID: 28620883)
      Lancet. 2011 Aug 27;378(9793):771-84. (PMID: 21802721)
      N Engl J Med. 2023 May 4;388(18):1645-1656. (PMID: 37133584)
    • Contributed Indexing:
      Keywords: breast cancer; decision-making; endocrine therapy; netnography; online forum
    • الرقم المعرف:
      0 (Antineoplastic Agents, Hormonal)
    • الموضوع:
      Date Created: 20251209 Date Completed: 20251209 Latest Revision: 20251212
    • الموضوع:
      20251212
    • الرقم المعرف:
      PMC12688053
    • الرقم المعرف:
      10.2196/82016
    • الرقم المعرف:
      41364788